A poor prognosis.
Johnson & Johnson, a global leader in the treatment of diabetes, saw the writing on the wall. Market forces were driving down margins in this important area of their business. Yet incidence of diabetes is growing worldwide. What opportunities were there to shape the treatment of this disease and prepare for a changing marketplace?
A treatment. And a cure.
Working closely with the client, DSI identified the forces that will affect diabetes treatment in the years to come and targeted patient segments that were underserved by J&J. We helped the client develop a strategy to influence the disease’s future treatment environment. Using scenario planning and other techniques, the company reallocated resources to mitigate risk and increase their potential return on investment. J&J also sought out alliances and partnerships as new engines of growth.
We also helped the company define a common vision for its five independent business units. United by this understanding, J&J has opened new internal lines of communication and is sharing resources and expertise across the franchise.
In the end, the client realized that 35% of future revenues will come from patient segments they don’t currently serve. By investing in a little advance planning J&J can build a tremendous competitive advantage.